Clinical Trial Detail

NCT ID NCT02101021
Title Gemcitabine and Nab-paclitaxel Combined With Momelotinib in Participants With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma
Recruitment Terminated
Gender both
Phase Phase II
Variant Requirements No
Sponsors Gilead Sciences
Indications

pancreatic ductal adenocarcinoma

Therapies

Gemcitabine + Nab-paclitaxel

Momelotinib

Age Groups: adult

No variant requirements are available.